Given the substantially improved anti-tumour immune responses and anti-Lag3 efficacy following CX-5461 treatment, dual blockading of ribosome biogenesis and LAG3 may be efficacious in immunotherapeutic-resistance cases and is considered a beneficial therapeutic approach. The gene discussed is LAG3; the disease is neoplasm.